Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene Expression Clear all
Terminated Phase 2 Interventional Results available

Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

NCT00343512
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, protein expression analysis, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 19, 2026, 1:24 PM EDT
Completed No phase listed Observational

CTC Immune Checkpoint

NCT02456571
View directory record Official record
Conditions
Prostate Cancer
Interventions
CTC biomarker expression prevalence
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 19, 2026, 1:24 PM EDT
Completed No phase listed Observational

Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps

NCT00898378
View directory record Official record
Conditions
Colorectal Cancer, Healthy, no Evidence of Disease, Precancerous Condition
Interventions
gene expression analysis, polymerase chain reaction, polymorphism analysis, protein expression analysis, proteomic profiling, gas chromatography, laboratory biomarker analysis, liquid chromatography, mass spectrometry, questionnaire administration
Genetic · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 19, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189
View directory record Official record
Conditions
Healthy, Asthma
Interventions
JNJ-43260295, Placebo, Nasal Allergen Challenge
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 19, 2026, 1:24 PM EDT
Completed No phase listed Observational

Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer

NCT00340847
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 1:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

NCT04439149
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
PI3K-beta Inhibitor GSK2636771
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 19, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

NCT00353158
View directory record Official record
Conditions
Healthy Volunteers, Fungal Infections, Bacterial Infections
Interventions
Doxycycline, Voriconazole
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
8 Years to 100 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 1:24 PM EDT
Withdrawn Phase 1 Interventional

Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease

NCT05340426
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
UKidney
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 19, 2026, 1:24 PM EDT
Not listed No phase listed Observational

TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)

NCT00985049
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 19, 2026, 1:24 PM EDT
Completed No phase listed Observational

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

NCT00379678
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 19, 2026, 1:24 PM EDT
Recruiting No phase listed Observational

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

NCT06008938
View directory record Official record
Conditions
Hemophilia B
Interventions
HEMGENIX, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2043
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 19, 2026, 1:24 PM EDT
Terminated No phase listed Observational

Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

NCT03290508
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prolaris Testing
Diagnostic Test
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
65 Years and older · Male only
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
34
States / cities
Homewood, Alabama • Mesa, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 19, 2026, 1:24 PM EDT
Active, not recruiting No phase listed Observational

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

NCT05424783
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate
Other
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 76 Years · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 1:24 PM EDT
Completed Not applicable Interventional

Hula, a Physical Activity Intervention for Female-Cancer Survivors

NCT02351479
View directory record Official record
Conditions
Physical Activity, Breast Cancer, Cervical Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Hula
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
21 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 19, 2026, 1:24 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

NCT03326076
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
Diagnostic Test · Other
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
72
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 19, 2026, 1:24 PM EDT
Completed Not applicable Interventional

TearCare MGX™ System With and Without Warming Hold

NCT07365735
View directory record Official record
Conditions
Meibomian Gland Dysfunction (Disorder)
Interventions
localized heat therapy
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 19, 2026, 1:24 PM EDT
Active, not recruiting No phase listed Observational

Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia

NCT00898456
View directory record Official record
Conditions
Leukemia
Interventions
gene expression analysis, molecular genetic technique, polymorphism analysis, protein expression analysis, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 19, 2026, 1:24 PM EDT
Terminated No phase listed Observational

5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results

NCT02355574
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
Not listed
Lead sponsor
Castle Biosciences Incorporated
Industry
Eligibility
16 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Louisville, Kentucky • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 19, 2026, 1:24 PM EDT
Terminated No phase listed Observational

Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

NCT03057743
View directory record Official record
Conditions
METASTATIC BREAST CANCER
Interventions
Positron emission tomography (PET/CT) imaging, radiotracer [18F]ISO-1
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 19, 2026, 1:24 PM EDT
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

NCT04524689
View directory record Official record
Conditions
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Interventions
SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 19, 2026, 1:24 PM EDT
Completed No phase listed Observational

Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer

NCT00806650
View directory record Official record
Conditions
Kidney Cancer
Interventions
gene expression analysis, protein expression analysis, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method
Genetic · Diagnostic Test · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 19, 2026, 1:24 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy

NCT03089476
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Food Allergy
Interventions
Evaluating atopy in infants, Evaluating TEWL and STS in adults
Other
Lead sponsor
National Jewish Health
Other
Eligibility
34 Weeks to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 19, 2026, 1:24 PM EDT
Terminated No phase listed Observational

TruGraf® Testing in High-Risk Kidney Transplant Recipients

NCT04266613
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
TruGraf® Testing
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 19, 2026, 1:24 PM EDT
Terminated No phase listed Observational

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)

NCT02121899
View directory record Official record
Conditions
Lung Cancer, NSCLC, NSCLC Adenocarcinoma
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 19, 2026, 1:24 PM EDT